These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7784310)

  • 1. Pharmacology of competitive inhibitors of HMG-CoA reductase.
    Corsini A; Maggi FM; Catapano AL
    Pharmacol Res; 1995 Jan; 31(1):9-27. PubMed ID: 7784310
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
    Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
    Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
    Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
    Del Puppo M; Rauli S; Galli Kienle M
    Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
    Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R
    Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
    [No Abstract]   [Full Text] [Related]  

  • 10. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
    Sirtori CR
    Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
    Bard JM; Luc G; Douste-Blazy P; Drouin P; Ziegler O; Jacotot B; Dachet C; De Gennes JL; Fruchart JC
    Eur J Clin Pharmacol; 1989; 37(6):545-50. PubMed ID: 2693115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase.
    Endo A
    J Med Chem; 1985 Apr; 28(4):401-5. PubMed ID: 3981532
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin-like growth factor I enhancement of steroidogenesis by bovine granulosa cells and thecal cells: dependence on de novo cholesterol synthesis.
    Spicer LJ; Hamilton TD; Keefer BE
    J Endocrinol; 1996 Dec; 151(3):365-73. PubMed ID: 8994382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
    Bernini F; Didoni G; Bonfadini G; Bellosta S; Fumagalli R
    Atherosclerosis; 1993 Dec; 104(1-2):19-26. PubMed ID: 8141843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
    Nagata Y; Hidaka Y; Ishida F; Kamei T
    Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins do more than just lower cholesterol.
    Vaughan CJ; Murphy MB; Buckley BM
    Lancet; 1996 Oct; 348(9034):1079-82. PubMed ID: 8874463
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
    Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
    Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.